MannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, will participate in a Fireside Chat at the H.C. Wainwright Bioconnect 2021 Conference. This event will be available on demand starting January 11, 2021, at 6:00 am (ET). Interested viewers can access the webcast link from the Events & Presentations section on MannKind's website. The replay will remain accessible for 14 days post-event. MannKind specializes in inhaled therapies for endocrine and orphan lung diseases, including Afrezza, the only inhaled ultra rapid-acting mealtime insulin in the U.S.

WESTLAKE VILLAGE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright Bioconnect 2021 Conference which will be available on demand starting on January 11, 2021 at 6:00 am (ET). Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.

About MannKind Corporation

MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Company Contact:
818-661-5000
ir@mannkindcorp.com

FAQ

What event is MannKind Corporation CEO participating in?

MannKind Corporation CEO Michael Castagna will participate in the H.C. Wainwright Bioconnect 2021 Conference.

When is the Fireside Chat for MannKind Corporation scheduled?

The Fireside Chat will be available on demand starting January 11, 2021, at 6:00 am (ET).

How can I access the MannKind Corporation presentation?

The presentation can be accessed through the Events & Presentations section of MannKind's website.

How long will the MannKind Corporation webcast be available?

The webcast replay will be available for 14 days following the live presentation.

What is Afrezza, related to MannKind Corporation?

Afrezza is the first FDA-approved inhaled ultra rapid-acting mealtime insulin available by prescription in the U.S.